BioVie Prices $4.74M Registered Direct at $1.60 With Full Warrant Package
BIVI sits 55% above its 52-week low of $0.82 on light trading volume (0.2× avg).
Summary
BioVie priced a $4.74 million registered direct — 960,000 shares at $1.60 plus 2,002,500 pre-funded warrants — with 2,962,500 common warrants at $1.70 in a concurrent private placement, netting about $4.23 million. New investors take $0.24 per share of immediate dilution.
Key Events · Financing and Capital Events · BIVI
-
Priced $4.74M Registered Direct
960,000 shares at $1.60 plus 2,002,500 pre-funded warrants at $1.5999 for gross proceeds of $4,739,799.75, versus a $1.73 last reported sale price on November 3, 2026.
-
Warrant Overhang From Private Placement
2,962,500 common warrants (100% of shares and pre-funded warrants sold) struck at $1.70, exercisable six months after issuance and expiring five years from the initial exercise date; a resale registration is due within 30 days.
-
Net Proceeds and Fees
Net proceeds of approximately $4.23 million after a 7.0% placement agent cash fee of $331,785.98 and estimated offering expenses of about $175,000; proceeds earmarked for working capital and general corporate purposes.
-
Immediate Dilution to New Buyers
As-further-adjusted net tangible book value of $1.36 per share versus the $1.60 offering price implies $0.24 per share of immediate dilution; shares outstanding after the offering are 11,653,888 assuming full exercise of the pre-funded warrants.
Analysis · BIVI · Life Sciences
BioVie is raising roughly $4.74 million gross — about $4.23 million net after a 7.0% A.G.P. fee — by selling 960,000 shares at $1.60 and 2,002,500 pre-funded warrants at $1.5999, alongside a concurrent private placement of 2,962,500 common warrants struck at $1.70. The offering price sits below the $1.73 last reported sale on November 3, and new buyers absorb $0.24 per share of immediate dilution against a $1.36 as-further-adjusted net tangible book value. For a company that reported a $22.1M annual loss with a going-concern warning, this cash extends runway but is small relative to the burn, and the warrant overhang (plus a resale registration due within 30 days) caps any upside from the raise. The 60-day issuance lock-up and the six-month wait before the common warrants become exercisable limit near-term supply, but the ATM remains available after 15 days post-closing.
How filings like this one have moved
In the 30 days to Nov 6, 2026, 44.9% of the 1410 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.36%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, BIVI was trading at $1.27 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $11.4M. The 52-week trading range was $0.82 to $3.79. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.